NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/08/2025
Voltar para busca
Dado oficial do USPTO
IMMUNOSCORE IC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
IMMUNOSCORE IC
ST13
US500000079342738Classe
5, 9, 42, 44
Pedido
79342738
Registro
7318047
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
15/08/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 42, 44
Data de depósito
29/04/2022
Data de registro
05/03/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/03/2024
Última transação
15/08/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
34
Localização do titular
FR
Examinador
EISNACH, MICHAEL
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
VERACYTE
Representantes
Rosaleen H. Chou Knobbe, Martens, Olson & Bear, LLP
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical productspharmaceutical products for use in the treatment of cancer; chemical preparations for medical and pharmaceutical usenamely for use in the treatment of cancer; biological reagents for medical use for providing information on diagnostics or identification of biological systems; biological reagents for providing information on diagnostics or identification of biological systems for medical use; immunological reagents for medical use; biological reagents for medical diagnosis; diagnostic kits comprising medical diagnostic reagents and medical diagnostic tests for the diagnosis of cancer and for the evaluation of a patient's reaction time to cancer treatments; biological reagents for medical research; biological reagents for medical use; biological reagents for clinical diagnosis
Classe 9
Downloadable or recorded software for diagnosisprognosismonitoringprediction of reactions to treatment and continuous evaluation analysis and study of a cancer or tumors; downloadable application software in the field of clinical biology for diagnosisprognosismonitoringprediction of reactions to treatment and continuous evaluation analysis and study of a cancer or tumors
Classe 42
Researchdevelopmenttechnical design and scientific testing servicesnamely scientific research for relating to cancer treatment; industrial analysis and research services in the fields of immuno-oncology and cancer research; clinical trial servicesnamely providing laboratory testing in clinical trials; tests in laboratoriesnamely in the fields of immuno-oncology and cancer research; development of testing methods for others in the fields of immuno-oncology and cancer research; researchdevelopmenttechnical designtestingconsultancy and analysis services in the field of immuno-oncology; research services in the field of genome and immune index analysis; design and development of software in the field of biology
Classe 44
Medical analysis services for the diagnosis of cancer and for the evaluation of a patient's reaction time to cancer treatments; medical assistance; medical diagnostics and diagnostics in the field of medicinenamely in the fields of immuno-oncology and cancer research; genetic analysis servicesnamely in the fields of immuno-oncology and cancer research
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/06/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
05/03/2024
GPNX
NOTIFICATION PROCESSED BY IB
19/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/12/2023
PUBO
PUBLISHED FOR OPPOSITION
19/12/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/12/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/11/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
29/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/11/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/11/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
22/11/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/10/2023
RFNT
REFUSAL PROCESSED BY IB
10/05/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
18/04/2023
RFRR
REFUSAL PROCESSED BY MPU
18/04/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/02/2023
CNRT
NON-FINAL ACTION WRITTEN
27/02/2023
DOCK
ASSIGNED TO EXAMINER
17/02/2023
MAFR
APPLICATION FILING RECEIPT MAILED
21/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/06/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/06/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IMMUNOSCORE IC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.